Pharmacological and x-ray structural characterization of a novel selective androgen receptor modulator: potent hyperanabolic stimulation of skeletal muscle with hypostimulation of prostate in rats.

A novel, highly potent, orally active, nonsteroidal tissue selective androgen receptor (AR) modulator (BMS-564929) has been identified, and this compound has been advanced to clinical trials for the treatment of age-related functional decline. BMS-564929 is a subnanomolar AR agonist in vitro, is highly selective for the AR vs. other steroid hormone receptors, and exhibits no significant interactions with SHBG or aromatase. Dose response studies in castrated male rats show that BMS-564929 is substantially more potent than testosterone (T) in stimulating the growth of the levator ani muscle, and unlike T, highly selective for muscle vs. prostate. Key differences in the binding interactions of BMS-564929 with the AR relative to the native hormones were revealed through x-ray crystallography, including several unique contacts located in specific helices of the ligand binding domain important for coregulatory protein recruitment. Results from additional pharmacological studies effectively exclude alternative mechanistic contributions to the observed tissue selectivity of this unique, orally active androgen. Because concerns regarding the potential hyperstimulatory effects on prostate and an inconvenient route of administration are major drawbacks that limit the clinical use of T, the potent oral activity and tissue selectivity exhibited by BMS-564929 are expected to yield a clinical profile that provides the demonstrated beneficial effects of T in muscle and other tissues with a more favorable safety window.

[1]  J. Dalton,et al.  Chemistry and structural biology of androgen receptor. , 2005, Chemical reviews.

[2]  Myles Brown,et al.  Molecular Determinants for the Tissue Specificity of SERMs , 2002, Science.

[3]  A. Matsumoto,et al.  Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. , 2005, The Journal of clinical endocrinology and metabolism.

[4]  R. Martins,et al.  Relationship between testosterone, sex hormone binding globulin and plasma amyloid beta peptide 40 in older men with subjective memory loss or dementia. , 2003, Journal of Alzheimer's disease : JAD.

[5]  Howard M. Einspahr,et al.  Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[6]  Bin He,et al.  Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance. , 2004, Molecular cell.

[7]  A. Matsumoto.  Andropause: clinical implications of the decline in serum testosterone levels with aging in men. , 2002, The journals of gerontology. Series A, Biological sciences and medical sciences.

[8]  N. Heinrich,et al.  Different ligands–different receptor conformations: Modeling of the hERα LBD in complex with agonists and antagonists , 2001, Medicinal research reviews (Print).

[9]  Duane D. Miller,et al.  A Selective Androgen Receptor Modulator for Hormonal Male Contraception , 2005, Journal of Pharmacology and Experimental Therapeutics.

[10]  A. Iranmanesh,et al.  Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. , 2000, The Journal of clinical endocrinology and metabolism.

[11]  M. Gelfand,et al.  Androgen and estrogen-androgen hormone replacement therapy: a review of the safety literature, 1941 to 1996. , 1997, Clinical therapeutics.

[12]  A. Dobs,et al.  Hypogonadism and androgen replacement therapy in elderly men. , 2001, The American journal of medicine.

[13]  P J Garry,et al.  Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. , 1997, Metabolism: clinical and experimental.

[14]  B. Katzenellenbogen,et al.  Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology , 2000, The Journal of Steroid Biochemistry and Molecular Biology.

[15]  Duane D. Miller,et al.  Structural basis for antagonism and resistance of bicalutamide in prostate cancer , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[16]  K. Yarasheski,et al.  Treatment with oxandrolone and the durability of effects in older men. , 2004, Journal of applied physiology.

[17]  E. Metter,et al.  Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. , 2001, The Journal of clinical endocrinology and metabolism.

[18]  B. Katzenellenbogen,et al.  Conformational Changes and Coactivator Recruitment by Novel Ligands for Estrogen Receptor-α and Estrogen Receptor-β: Correlations with Biological Character and Distinct Differences among SRC Coactivator Family Members. , 2000, Endocrinology.

[19]  Paul Webb,et al.  Conformational adaptation of nuclear receptor ligand binding domains to agonists: Potential for novel approaches to ligand design , 2005, The Journal of Steroid Biochemistry and Molecular Biology.

[20]  A. Matsumoto,et al.  Testosterone Supplementation Therapy for Older Men: Potential Benefits and Risks , 2003, Journal of the American Geriatrics Society.

[21]  A. Morgentaler,et al.  Risks of testosterone-replacement therapy and recommendations for monitoring. , 2004, The New England journal of medicine.

[22]  J. Culberson,et al.  Role of androgens in mild cognitive impairment and possible interventions during andropause. , 2003, Medical hypotheses.

[23]  A. Araujo,et al.  Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. , 2002, The Journal of clinical endocrinology and metabolism.

[24]  T. Brown,et al.  Identification and Characterization of a Novel Androgen Response Element Composed of a Direct Repeat* , 1997, The Journal of Biological Chemistry.

[25]  G. Cunningham,et al.  Andropause: is androgen replacement therapy indicated for the aging male? , 2005, Annual review of medicine.

[26]  J. Berlin,et al.  Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. , 1999, The Journal of clinical endocrinology and metabolism.

[27]  J. Kaufman,et al.  The decline of androgen levels in elderly men and its clinical and therapeutic implications. , 2005, Endocrine reviews.

[28]  Tzu-Ming Chu,et al.  Linking ligand-induced alterations in androgen receptor structure to differential gene expression: a first step in the rational design of selective androgen receptor modulators. , 2006, Molecular endocrinology.

[29]  D. McDonnell,et al.  Definition of the molecular and cellular mechanisms underlying the tissue-selective agonist/antagonist activities of selective estrogen receptor modulators. , 2002, Recent progress in hormone research.

[30]  S. Bhasin,et al.  Effects of an oral androgen on muscle and metabolism in older, community-dwelling men. , 2003, American journal of physiology. Endocrinology and metabolism.

[31]  S. Wolf,et al.  Testosterone: Selective androgen receptor modulators (SARMs) , 2004 .

[32]  A. Negro-Vilar.  Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium. , 1999, The Journal of clinical endocrinology and metabolism.

[33]  K. Kish,et al.  Structure based approach to the design of bicyclic-1H-isoindole-1,3(2H)-dione based androgen receptor antagonists. , 2005, Bioorganic & medicinal chemistry letters.

[34]  M. S. Khan,et al.  Androgen and estrogen signaling at the cell membrane via G-proteins and cyclic adenosine monophosphate , 1999, Steroids.

[35]  R. Wolfe,et al.  Testosterone administration to older men improves muscle function: molecular and physiological mechanisms. , 2002, American journal of physiology. Endocrinology and metabolism.

[36]  J. Veldhuis,et al.  Clinical review 171: The rationale, efficacy and safety of androgen therapy in older men: future research and current practice recommendations. , 2004, The Journal of clinical endocrinology and metabolism.

[37]  Androgens, andropause and neurodegeneration: exploring the link between steroidogenesis, androgens and Alzheimer's disease. , 2005, Cellular and molecular life sciences : CMLS.

[38]  J. Dunn,et al.  Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma. , 1981, The Journal of clinical endocrinology and metabolism.

[39]  D. Moras,et al.  Specific Recognition of Androgens by Their Nuclear Receptor , 2000, The Journal of Biological Chemistry.

[40]  Richard A. Anderson,et al.  Evidence for tissue selectivity of the synthetic androgen 7 alpha-methyl-19-nortestosterone in hypogonadal men. , 2003, The Journal of clinical endocrinology and metabolism.

[41]  L. Hamann,et al.  Discovery of a potent, orally active, nonsteroidal androgen receptor agonist: 4-ethyl-1,2,3,4-tetrahydro-6- (trifluoromethyl)-8-pyridono[5,6-g]- quinoline (LG121071). , 1999, Journal of medicinal chemistry.

[42]  C. Heinlein,et al.  The roles of androgen receptors and androgen-binding proteins in nongenomic androgen actions. , 2002, Molecular endocrinology.

[43]  Shalender Bhasin,et al.  Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. , 2005, The Journal of clinical endocrinology and metabolism.

[44]  Y. Shang,et al.  Formation of the androgen receptor transcription complex. , 2002, Molecular cell.

[45]  Carolyn L. Smith,et al.  Molecular mechanisms of selective estrogen receptor modulator (SERM) action. , 2000, The Journal of pharmacology and experimental therapeutics.

[46]  C. Heinlein,et al.  Androgen receptor (AR) coregulators: an overview. , 2002, Endocrine reviews.

[47]  David Handelsman,et al.  A double-blind, placebo-controlled, randomized clinical trial of transdermal dihydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiency. , 2001, The Journal of clinical endocrinology and metabolism.

[48]  J. Sorkin,et al.  Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial. , 2002 .

[49]  Bert W O'Malley,et al.  Coregulator function: a key to understanding tissue specificity of selective receptor modulators. , 2004, Endocrine reviews.